Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting CDK4/6 as an interception strategy for intraductal papillary mucinous neoplasia

Award Number: K01CA297135
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 04/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

Targeting CDK4/6 as an interception strategy for intraductal papillary mucinous neoplasia - ABSTRACT Intraductal papillary mucinous neoplasms (IPMN) are common cystic neoplasms of the pancreas that may progress to pancreatic ductal adenocarcinoma (PDAC), a lethal disease with a current 5-year survival rate of 12%. The management for patients with IPMN high-risk features, mandates surgical resection in patients fit for surgery. While surgical resection is curative for some individuals, pancreatectomy carries significant risk of postoperative morbidity, and IPMNs reoccur in 30 – 60% of patients with invasive disease. Strikingly, 4-5% of patients with IPMN biopsies containing pathological features that reveal high grade dysplasia will be diagnosed with invasive PDAC within 5 years of their pancreatectomy. As such, identifying effective interception strategies for IPMN is a significant unmet need. Here we have based our research approach on reverse translational experiments where we have identified that the presence of co-oncogenic driver mutations in KRAS and GNAS renders multiple cancer types originating from different organs susceptible to CDK4/6 inhibition in patients. As ~70% of IPMN tumors contain KRAS and GNAS co-mutation, here we will determine the impact of CDK4/6 inhibition on IPMN tumor progression in genetically modified mice and PDX models of IPMN, where we can tightly regulate the timing, dosing, tumor genetics, as well as analyze tumor responses in pre-clinical models. In addition to studying endpoints of tumor progression and survival, we will determine the effects of CDK4/6 inhibition on the tumor microenvironment of IPMN. The results of these studies will provide key translational data that will propel future human clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $166,037 )
2026	2026	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Cancer Research Manpower	000	2	3/3/2026	NON-COMPETING CONTINUATION	$166,037
														Subtotal = $166,037

Issue Date FY: 2025 ( Subtotal = $166,037 )
2025	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Cancer Research Manpower	000	1	3/21/2025	NEW	$166,037
														Subtotal = $166,037

Grand Total All Awards = $332,074

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting CDK4/6 as an interception strategy for intraductal papillary mucinous neoplasia

Award Number: K01CA297135

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 04/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer